SCM
CRDF icon

Sterling Capital Management’s Cardiff Oncology CRDF Stock Holding History

Sterling Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,276
Closed -$2.07K – 3305
2026
Q1 		$2.07K Sell
1,276
-1,179
-48% -$2.42K ﹤0.01% 2987
2025
Q4 		$6.9K Buy
2,455
+119
+5% +$276 ﹤0.01% 2775
2025
Q3 		$4.81K Buy
2,336
+1,322
+130% +$3.65K ﹤0.01% 2773
2025
Q2 		$3.19K Buy
1,014
+379
+60% +$1.16K ﹤0.01% 2753
2025
Q1 		$1.99K Sell
635
-200
-24% -$791 ﹤0.01% 2604
2024
Q4 		$3.62K Buy
835
+743
+808% +$2.32K ﹤0.01% 2587
2024
Q3 		$246 Buy
+92
New +$217 ﹤0.01% 3082

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sterling Capital Management's CRDF Position: Q2 2026 in Review

Sterling Capital Management sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 1,276 shares — an estimated $2.07K sold.

Sterling Capital Management first reported a position in CRDF in Q3 2024 and held it in 7 quarters. The position peaked at $6.9K in Q4 2025. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Sterling Capital Management reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
  • Sterling Capital Management sold 1,276 Cardiff Oncology shares in Q2 2026, an estimated $2.07K.
  • Sterling Capital Management first reported a position in Cardiff Oncology in Q3 2024 and held it in 7 quarters.
  • Sterling Capital Management's Cardiff Oncology position peaked at $6.9K in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.